20
April
2018
|
01:00 PM
America/New_York

Lupus Subgroup Responds to Anti-CD22

According to a recent study, the monoclonal antibody epratuzumab could deplete B-cells in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, MedPage Today reported.

HSS rheumatologist Kyriakos A. Kirou, MD, DSc, FACP, who was not involved with the study, commented on the results.

"This finding, if confirmed, may allow for a more patient-targeted approach when treating lupus, a notoriously heterogeneous disease," Dr. Kirou said.

"More epratuzumab studies are needed in patients with SLE and associated Sjogren's syndrome before we can conclude that this treatment is effective in this subgroup of patients," he added.

Read the full article at medpagetoday.com